Clinical Trial Update: MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab plus BEAM conditioning with autologous stem cell transplant for relapsed Hodgkin lymphoma. The study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Carmustine (carmustine)
• Etoposide (Etoposide)
• KEYTRUDA (PEMBROLIZUMAB)
• Melphalan (Melphalan)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma | Phase 2 | Status: RECRUITING